W
hile THAs enhance the quality of life, a surgical site infection (SSI) can be extremely costly and morbid, sometimes even negating the benefits of the surgery. As the number of elective arthroplasties are expected to increase, the pressure to reduce the risk of infection also grows. There are strong evidence-based recommendations, such as alcohol-containing operative site antisepsis, appropriate antimicrobial prophylaxis, and the maintenance of perioperative normothermia, that when combined into perioperative bundles (and executed well) can greatly reduce the risk of SSIs [1] . In this lofty pursuit to further prevent infections, many are also performing additional interventions such as Staphylococcus aureus decolonization and even empiric cutaneous antiseptic bathing as evaluated by Kapadia and colleagues.
While bathing or showering with a skin antiseptic is a well-accepted method of reducing the number of bacteria on the skin, this practice alone has not definitively shown to reduce SSIs [3] . A Cochrane Review [7] evaluated the evidence for preoperative bathing or showering with antiseptics for preventing SSIs. Of the seven randomized controlled trials evaluating 4% chlorhexidine gluconate (CHG) preoperative bathing or showering, there was no clear benefit compared to placebo or bar soap [7] . However, several of the trials included in that analysis were more than 20 years old and there were a number of methodological limitations in those studies, especially in their infection surveillance for SSIs and how the CHG was applied.
The current study by Kapadia and colleagues did not have those same limitations, and has a number of notable strengths. For example, the inclusion of revision arthroplasties, a population recognized as a higher risk for SSIs, which improves the generalizability of the findings. In addition, infection surveillance was performed for 1 year after the operation instead of just 90 days, as seen in some recent studies [6] or even less than a week as seen in an older trial [5] which improves the strength of this study. The intervention itself was also simple and compliance was easily measured, making this a pragmatic study.
Where Do We Need To Go?
While the work of Kapadia and colleagues addressed a number of shortcomings in prior studies on this topic, like all good research, it also leads to more questions. In particular, what modifiable risk factors can we affect in the high-risk patient, as classified by the National Healthcare Safety Network's risk index model. Should the intervention to reduce SSIs have a larger impact on the group of people who are at highest risk for an SSI? We also need to further investigate what factors affect adherence to this patient-centered intervention. Lastly, SSI-prevention science has advanced so much in the past few decades that much of the low-hanging fruit has been plucked, and simple additional interventions are unlikely to substantially reduce the absolute number of infections. Thus, we may need to better understand how this current intervention can be included in more complex preadmission bundles that address more than one modifiable risk factor, for example smoking, uncontrolled blood glucose, malnutrition, and S aureus colonization [4, 6] .
How Do We Get There?
This is an important study that adds to the growing body of evidence that preadmission skin antisepsis likely provides a benefit in reducing SSIs in elective arthroplasties. Ideally, we would evaluate each intervention with randomized controlled trials to determine if each adds a risk benefit, but these types are trials would be costly when evaluating the effect of one simple intervention in an already rare outcome. However, studies evaluating patient education, how to standardize the application of the CHG, and how to increase adherence to the practice will maximize any benefit of a patientcentered intervention such as the one studied by Kapadia and colleagues. Prospective studies investigating behavior modification strategies, such as Edmiston and colleagues [2] , who showed that electronic reminders increased CHG concentration on the patients' skin are going to be crucial.
In addition, Schweizer and colleagues [6] included empiric cutaneous antisepsis along with targeted S aureus decolonization and showed a significant reduction in SSIs due to S aureus but not SSIs due to any pathogen. Therefore, prospective trials evaluating a multifaceted approach addressing other modifiable risk factors will be of greatest interest to healthcare systems, payers, and ultimately patients.
For now, as we gain evidence for this simple and inexpensive intervention that is unlikely to harbor much risk, we may want to include empiric cutaneous antisepsis as a part of a preadmission bundle that also includes other practices such as screening for uncontrolled blood glucose and malnutrition, targeted S aureus decolonization, and strategies that emphasize overall adherence to the bundle.
